{"pmid":32403217,"title":"Hypertension, Thrombosis, Kidney Failure, and Diabetes: Is COVID-19 an Endothelial Disease? A Comprehensive Evaluation of Clinical and Basic Evidence.","text":["Hypertension, Thrombosis, Kidney Failure, and Diabetes: Is COVID-19 an Endothelial Disease? A Comprehensive Evaluation of Clinical and Basic Evidence.","The symptoms most commonly reported by patients affected by coronavirus disease (COVID-19) include cough, fever, and shortness of breath. However, other major events usually observed in COVID-19 patients (e.g., high blood pressure, arterial and venous thromboembolism, kidney disease, neurologic disorders, and diabetes mellitus) indicate that the virus is targeting the endothelium, one of the largest organs in the human body. Herein, we report a systematic and comprehensive evaluation of both clinical and preclinical evidence supporting the hypothesis that the endothelium is a key target organ in COVID-19, providing a mechanistic rationale behind its systemic manifestations.","J Clin Med","Sardu, Celestino","Gambardella, Jessica","Morelli, Marco Bruno","Wang, Xujun","Marfella, Raffaele","Santulli, Gaetano","32403217"],"abstract":["The symptoms most commonly reported by patients affected by coronavirus disease (COVID-19) include cough, fever, and shortness of breath. However, other major events usually observed in COVID-19 patients (e.g., high blood pressure, arterial and venous thromboembolism, kidney disease, neurologic disorders, and diabetes mellitus) indicate that the virus is targeting the endothelium, one of the largest organs in the human body. Herein, we report a systematic and comprehensive evaluation of both clinical and preclinical evidence supporting the hypothesis that the endothelium is a key target organ in COVID-19, providing a mechanistic rationale behind its systemic manifestations."],"journal":"J Clin Med","authors":["Sardu, Celestino","Gambardella, Jessica","Morelli, Marco Bruno","Wang, Xujun","Marfella, Raffaele","Santulli, Gaetano"],"date":"2020-05-15T11:00:00Z","year":2020,"_id":"32403217","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.3390/jcm9051417","keywords":["ace2, acute kidney injury","covid","kawasaki disease","blood pressure","catepsin","coronavirus","cytokine storm","endothelium","heparin"],"topics":["Treatment","Mechanism","Diagnosis"],"weight":1,"_version_":1666802845411704832,"score":9.490897,"similar":[{"pmid":32464367,"title":"The neurology of COVID-19 revisited: A proposal from the Environmental Neurology Specialty Group of the World Federation of Neurology to implement international neurological registries.","text":["The neurology of COVID-19 revisited: A proposal from the Environmental Neurology Specialty Group of the World Federation of Neurology to implement international neurological registries.","A comprehensive review of the neurological disorders reported during the current COVID-19 pandemic demonstrates that infection with SARS-CoV-2 affects the central nervous system (CNS), the peripheral nervous system (PNS) and the muscle. CNS manifestations include: headache and decreased responsiveness considered initial indicators of potential neurological involvement; anosmia, hyposmia, hypogeusia, and dysgeusia are frequent early symptoms of coronavirus infection. Respiratory failure, the lethal manifestation of COVID-19, responsible for 264,679 deaths worldwide, is probably neurogenic in origin and may result from the viral invasion of cranial nerve I, progressing into rhinencephalon and brainstem respiratory centers. Cerebrovascular disease, in particular large-vessel ischemic strokes, and less frequently cerebral venous thrombosis, intracerebral hemorrhage and subarachnoid hemorrhage, usually occur as part of a thrombotic state induced by viral attachment to ACE2 receptors in endothelium causing widespread endotheliitis, coagulopathy, arterial and venous thromboses. Acute hemorrhagic necrotizing encephalopathy is associated to the cytokine storm. A frontal hypoperfusion syndrome has been identified. There are isolated reports of seizures, encephalopathy, meningitis, encephalitis, and myelitis. The neurological diseases affecting the PNS and muscle in COVID-19 are less frequent and include Guillain-Barre syndrome; Miller Fisher syndrome; polyneuritis cranialis; and rare instances of viral myopathy with rhabdomyolysis. The main conclusion of this review is the pressing need to define the neurology of COVID-19, its frequency, manifestations, neuropathology and pathogenesis. On behalf of the World Federation of Neurology we invite national and regional neurological associations to create local databases to report cases with neurological manifestations observed during the on-going pandemic. International neuroepidemiological collaboration may help define the natural history of this worldwide problem.","J Neurol Sci","Roman, Gustavo C","Spencer, Peter S","Reis, Jacques","Buguet, Alain","Faris, Mostafa El Alaoui","Katrak, Sarosh M","Lainez, Miguel","Medina, Marco Tulio","Meshram, Chandrashekhar","Mizusawa, Hidehiro","Ozturk, Serefnur","Wasay, Mohammad","32464367"],"abstract":["A comprehensive review of the neurological disorders reported during the current COVID-19 pandemic demonstrates that infection with SARS-CoV-2 affects the central nervous system (CNS), the peripheral nervous system (PNS) and the muscle. CNS manifestations include: headache and decreased responsiveness considered initial indicators of potential neurological involvement; anosmia, hyposmia, hypogeusia, and dysgeusia are frequent early symptoms of coronavirus infection. Respiratory failure, the lethal manifestation of COVID-19, responsible for 264,679 deaths worldwide, is probably neurogenic in origin and may result from the viral invasion of cranial nerve I, progressing into rhinencephalon and brainstem respiratory centers. Cerebrovascular disease, in particular large-vessel ischemic strokes, and less frequently cerebral venous thrombosis, intracerebral hemorrhage and subarachnoid hemorrhage, usually occur as part of a thrombotic state induced by viral attachment to ACE2 receptors in endothelium causing widespread endotheliitis, coagulopathy, arterial and venous thromboses. Acute hemorrhagic necrotizing encephalopathy is associated to the cytokine storm. A frontal hypoperfusion syndrome has been identified. There are isolated reports of seizures, encephalopathy, meningitis, encephalitis, and myelitis. The neurological diseases affecting the PNS and muscle in COVID-19 are less frequent and include Guillain-Barre syndrome; Miller Fisher syndrome; polyneuritis cranialis; and rare instances of viral myopathy with rhabdomyolysis. The main conclusion of this review is the pressing need to define the neurology of COVID-19, its frequency, manifestations, neuropathology and pathogenesis. On behalf of the World Federation of Neurology we invite national and regional neurological associations to create local databases to report cases with neurological manifestations observed during the on-going pandemic. International neuroepidemiological collaboration may help define the natural history of this worldwide problem."],"journal":"J Neurol Sci","authors":["Roman, Gustavo C","Spencer, Peter S","Reis, Jacques","Buguet, Alain","Faris, Mostafa El Alaoui","Katrak, Sarosh M","Lainez, Miguel","Medina, Marco Tulio","Meshram, Chandrashekhar","Mizusawa, Hidehiro","Ozturk, Serefnur","Wasay, Mohammad"],"date":"2020-05-29T11:00:00Z","year":2020,"_id":"32464367","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1016/j.jns.2020.116884","keywords":["covid-19 neurological complications","coronavirus disease 2019","coronaviruses","endotheliitis","environmental neurology, mers","mers-cov","neuroepidemiology","neuropathology","pandemic","sars","sars-cov-1","sars-cov-2","viral neurotropism","zoonosis"],"locations":["ischemic","cytokine"],"topics":["Diagnosis","Mechanism"],"weight":1,"_version_":1668079521230749696,"score":160.19585},{"pmid":32469387,"title":"Neuropathogenesis and Neurologic Manifestations of the Coronaviruses in the Age of Coronavirus Disease 2019: A Review.","text":["Neuropathogenesis and Neurologic Manifestations of the Coronaviruses in the Age of Coronavirus Disease 2019: A Review.","Importance: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in December 2019, causing human coronavirus disease 2019 (COVID-19), which has now spread into a worldwide pandemic. The pulmonary manifestations of COVID-19 have been well described in the literature. Two similar human coronaviruses that cause Middle East respiratory syndrome (MERS-CoV) and severe acute respiratory syndrome (SARS-CoV-1) are known to cause disease in the central and peripheral nervous systems. Emerging evidence suggests COVID-19 has neurologic consequences as well. Observations: This review serves to summarize available information regarding coronaviruses in the nervous system, identify the potential tissue targets and routes of entry of SARS-CoV-2 into the central nervous system, and describe the range of clinical neurological complications that have been reported thus far in COVID-19 and their potential pathogenesis. Viral neuroinvasion may be achieved by several routes, including transsynaptic transfer across infected neurons, entry via the olfactory nerve, infection of vascular endothelium, or leukocyte migration across the blood-brain barrier. The most common neurologic complaints in COVID-19 are anosmia, ageusia, and headache, but other diseases, such as stroke, impairment of consciousness, seizure, and encephalopathy, have also been reported. Conclusions and Relevance: Recognition and understanding of the range of neurological disorders associated with COVID-19 may lead to improved clinical outcomes and better treatment algorithms. Further neuropathological studies will be crucial to understanding the pathogenesis of the disease in the central nervous system, and longitudinal neurologic and cognitive assessment of individuals after recovery from COVID-19 will be crucial to understand the natural history of COVID-19 in the central nervous system and monitor for any long-term neurologic sequelae.","JAMA Neurol","Zubair, Adeel S","McAlpine, Lindsay S","Gardin, Tova","Farhadian, Shelli","Kuruvilla, Deena E","Spudich, Serena","32469387"],"abstract":["Importance: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in December 2019, causing human coronavirus disease 2019 (COVID-19), which has now spread into a worldwide pandemic. The pulmonary manifestations of COVID-19 have been well described in the literature. Two similar human coronaviruses that cause Middle East respiratory syndrome (MERS-CoV) and severe acute respiratory syndrome (SARS-CoV-1) are known to cause disease in the central and peripheral nervous systems. Emerging evidence suggests COVID-19 has neurologic consequences as well. Observations: This review serves to summarize available information regarding coronaviruses in the nervous system, identify the potential tissue targets and routes of entry of SARS-CoV-2 into the central nervous system, and describe the range of clinical neurological complications that have been reported thus far in COVID-19 and their potential pathogenesis. Viral neuroinvasion may be achieved by several routes, including transsynaptic transfer across infected neurons, entry via the olfactory nerve, infection of vascular endothelium, or leukocyte migration across the blood-brain barrier. The most common neurologic complaints in COVID-19 are anosmia, ageusia, and headache, but other diseases, such as stroke, impairment of consciousness, seizure, and encephalopathy, have also been reported. Conclusions and Relevance: Recognition and understanding of the range of neurological disorders associated with COVID-19 may lead to improved clinical outcomes and better treatment algorithms. Further neuropathological studies will be crucial to understanding the pathogenesis of the disease in the central nervous system, and longitudinal neurologic and cognitive assessment of individuals after recovery from COVID-19 will be crucial to understand the natural history of COVID-19 in the central nervous system and monitor for any long-term neurologic sequelae."],"journal":"JAMA Neurol","authors":["Zubair, Adeel S","McAlpine, Lindsay S","Gardin, Tova","Farhadian, Shelli","Kuruvilla, Deena E","Spudich, Serena"],"date":"2020-05-30T11:00:00Z","year":2020,"_id":"32469387","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1001/jamaneurol.2020.2065","topics":["Treatment","Mechanism","Diagnosis"],"weight":1,"_version_":1668167109909151746,"score":147.10312},{"pmid":32399449,"pmcid":"PMC7213837","title":"Deep Vein Thrombosis and Pulmonary Embolism: Two Complications of COVID-19 Pneumonia?","text":["Deep Vein Thrombosis and Pulmonary Embolism: Two Complications of COVID-19 Pneumonia?","Coronavirus disease 19 (COVID-19) is a worldwide infection which was recently declared a global health emergency by the WHO Emergency Committee. The most common symptoms are fever and cough, which can progress to pneumonia, acute respiratory distress syndrome (ARDS) and/or end-organ failure. Risk factors associated with ARDS and death are older age, comorbidities (e.g., hypertension, diabetes, hyperlipidaemia), neutrophilia, and organ and coagulation dysfunction. Disseminated intravascular coagulation and coagulopathy can contribute to death. Anticoagulant treatment is associated with decreased mortality in severe COVID-19 pneumonia. In this report we describe two patients with COVID-19 pneumonia who developed venous thromboembolism. LEARNING POINTS: Deep vein thrombosis and pulmonary embolism can occur in patients with COVID-19 pneumonia.Low-molecular-weight heparin prophylaxis does not decrease the risk of venous thromboembolism (VTE) in COVID-19 pneumonia.In the presence of clinical signs and/or suspicion of VTE, compression ultrasound and echocardiography should be always performed, irrespective of disease stage.","Eur J Case Rep Intern Med","Poggiali, Erika","Bastoni, Davide","Ioannilli, Eva","Vercelli, Andrea","Magnacavallo, Andrea","32399449"],"abstract":["Coronavirus disease 19 (COVID-19) is a worldwide infection which was recently declared a global health emergency by the WHO Emergency Committee. The most common symptoms are fever and cough, which can progress to pneumonia, acute respiratory distress syndrome (ARDS) and/or end-organ failure. Risk factors associated with ARDS and death are older age, comorbidities (e.g., hypertension, diabetes, hyperlipidaemia), neutrophilia, and organ and coagulation dysfunction. Disseminated intravascular coagulation and coagulopathy can contribute to death. Anticoagulant treatment is associated with decreased mortality in severe COVID-19 pneumonia. In this report we describe two patients with COVID-19 pneumonia who developed venous thromboembolism. LEARNING POINTS: Deep vein thrombosis and pulmonary embolism can occur in patients with COVID-19 pneumonia.Low-molecular-weight heparin prophylaxis does not decrease the risk of venous thromboembolism (VTE) in COVID-19 pneumonia.In the presence of clinical signs and/or suspicion of VTE, compression ultrasound and echocardiography should be always performed, irrespective of disease stage."],"journal":"Eur J Case Rep Intern Med","authors":["Poggiali, Erika","Bastoni, Davide","Ioannilli, Eva","Vercelli, Andrea","Magnacavallo, Andrea"],"date":"2020-05-14T11:00:00Z","year":2020,"_id":"32399449","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.12890/2020_001646","keywords":["covid-19 pneumonia","deep vein thrombosis","heparin","pulmonary embolism","venous thromboembolism"],"locations":["Pneumonia"],"e_drugs":["Heparin"],"topics":["Case Report"],"weight":1,"_version_":1666714494762483713,"score":143.4356},{"pmid":32352535,"pmcid":"PMC7197627","title":"COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options.","text":["COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options.","The novel coronavirus disease (COVID-19) outbreak, caused by SARS-CoV-2, represents the greatest medical challenge in decades. We provide a comprehensive review of the clinical course of COVID-19, its comorbidities, and mechanistic considerations for future therapies. While COVID-19 primarily affects the lungs, causing interstitial pneumonitis and severe acute respiratory distress syndrome (ARDS), it also affects multiple organs, particularly the cardiovascular system. Risk of severe infection and mortality increase with advancing age and male sex. Mortality is increased by comorbidities: cardiovascular disease, hypertension, diabetes, chronic pulmonary disease, and cancer. The most common complications include arrhythmia (atrial fibrillation, ventricular tachyarrhythmia, and ventricular fibrillation), cardiac injury [elevated highly sensitive troponin I (hs-cTnI) and creatine kinase (CK) levels], fulminant myocarditis, heart failure, pulmonary embolism, and disseminated intravascular coagulation (DIC). Mechanistically, SARS-CoV-2, following proteolytic cleavage of its S protein by a serine protease, binds to the transmembrane angiotensin-converting enzyme 2 (ACE2) -a homologue of ACE-to enter type 2 pneumocytes, macrophages, perivascular pericytes, and cardiomyocytes. This may lead to myocardial dysfunction and damage, endothelial dysfunction, microvascular dysfunction, plaque instability, and myocardial infarction (MI). While ACE2 is essential for viral invasion, there is no evidence that ACE inhibitors or angiotensin receptor blockers (ARBs) worsen prognosis. Hence, patients should not discontinue their use. Moreover, renin-angiotensin-aldosterone system (RAAS) inhibitors might be beneficial in COVID-19. Initial immune and inflammatory responses induce a severe cytokine storm [interleukin (IL)-6, IL-7, IL-22, IL-17, etc.] during the rapid progression phase of COVID-19. Early evaluation and continued monitoring of cardiac damage (cTnI and NT-proBNP) and coagulation (D-dimer) after hospitalization may identify patients with cardiac injury and predict COVID-19 complications. Preventive measures (social distancing and social isolation) also increase cardiovascular risk. Cardiovascular considerations of therapies currently used, including remdesivir, chloroquine, hydroxychloroquine, tocilizumab, ribavirin, interferons, and lopinavir/ritonavir, as well as experimental therapies, such as human recombinant ACE2 (rhACE2), are discussed.","Cardiovasc Res","Guzik, Tomasz J","Mohiddin, Saidi A","Dimarco, Anthony","Patel, Vimal","Savvatis, Kostas","Marelli-Berg, Federica M","Madhur, Meena S","Tomaszewski, Maciej","Maffia, Pasquale","D'Acquisto, Fulvio","Nicklin, Stuart A","Marian, Ali J","Nosalski, Ryszard","Murray, Eleanor C","Guzik, Bartlomiej","Berry, Colin","Touyz, Rhian M","Kreutz, Reinhold","Wang, Dao Wen","Bhella, David","Sagliocco, Orlando","Crea, Filippo","Thomson, Emma C","McInnes, Iain B","32352535"],"abstract":["The novel coronavirus disease (COVID-19) outbreak, caused by SARS-CoV-2, represents the greatest medical challenge in decades. We provide a comprehensive review of the clinical course of COVID-19, its comorbidities, and mechanistic considerations for future therapies. While COVID-19 primarily affects the lungs, causing interstitial pneumonitis and severe acute respiratory distress syndrome (ARDS), it also affects multiple organs, particularly the cardiovascular system. Risk of severe infection and mortality increase with advancing age and male sex. Mortality is increased by comorbidities: cardiovascular disease, hypertension, diabetes, chronic pulmonary disease, and cancer. The most common complications include arrhythmia (atrial fibrillation, ventricular tachyarrhythmia, and ventricular fibrillation), cardiac injury [elevated highly sensitive troponin I (hs-cTnI) and creatine kinase (CK) levels], fulminant myocarditis, heart failure, pulmonary embolism, and disseminated intravascular coagulation (DIC). Mechanistically, SARS-CoV-2, following proteolytic cleavage of its S protein by a serine protease, binds to the transmembrane angiotensin-converting enzyme 2 (ACE2) -a homologue of ACE-to enter type 2 pneumocytes, macrophages, perivascular pericytes, and cardiomyocytes. This may lead to myocardial dysfunction and damage, endothelial dysfunction, microvascular dysfunction, plaque instability, and myocardial infarction (MI). While ACE2 is essential for viral invasion, there is no evidence that ACE inhibitors or angiotensin receptor blockers (ARBs) worsen prognosis. Hence, patients should not discontinue their use. Moreover, renin-angiotensin-aldosterone system (RAAS) inhibitors might be beneficial in COVID-19. Initial immune and inflammatory responses induce a severe cytokine storm [interleukin (IL)-6, IL-7, IL-22, IL-17, etc.] during the rapid progression phase of COVID-19. Early evaluation and continued monitoring of cardiac damage (cTnI and NT-proBNP) and coagulation (D-dimer) after hospitalization may identify patients with cardiac injury and predict COVID-19 complications. Preventive measures (social distancing and social isolation) also increase cardiovascular risk. Cardiovascular considerations of therapies currently used, including remdesivir, chloroquine, hydroxychloroquine, tocilizumab, ribavirin, interferons, and lopinavir/ritonavir, as well as experimental therapies, such as human recombinant ACE2 (rhACE2), are discussed."],"journal":"Cardiovasc Res","authors":["Guzik, Tomasz J","Mohiddin, Saidi A","Dimarco, Anthony","Patel, Vimal","Savvatis, Kostas","Marelli-Berg, Federica M","Madhur, Meena S","Tomaszewski, Maciej","Maffia, Pasquale","D'Acquisto, Fulvio","Nicklin, Stuart A","Marian, Ali J","Nosalski, Ryszard","Murray, Eleanor C","Guzik, Bartlomiej","Berry, Colin","Touyz, Rhian M","Kreutz, Reinhold","Wang, Dao Wen","Bhella, David","Sagliocco, Orlando","Crea, Filippo","Thomson, Emma C","McInnes, Iain B"],"date":"2020-05-01T11:00:00Z","year":2020,"_id":"32352535","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1093/cvr/cvaa106","keywords":["ace2","acute coronary syndrome","covid-19","cardiac","endothelium","microvascular","myocardial infarction","myocarditis","vascular","virus"],"locations":["tocilizumab"],"e_drugs":["remdesivir","Hydroxychloroquine","Ribavirin","lopinavir-ritonavir drug combination","Aldosterone","Chloroquine","tocilizumab"],"topics":["Treatment","Mechanism","Diagnosis"],"weight":1,"_version_":1666138495675006979,"score":124.956375},{"pmid":32464707,"title":"Macrothrombosis and stroke in patients with mild Covid-19 infection.","text":["Macrothrombosis and stroke in patients with mild Covid-19 infection.","Coronavirus disease 2019 (COVID-19) is a pandemic disease currently affecting millions of people worldwide. Its neurological implications are poorly understood, and further study is urgently required. A hypercoagulable state has been reported in patients with severe COVID-19, but nothing is known about coagulopathy in patients with milder disease. We describe cases of patients in New York City presenting with stroke secondary to large vessel thrombosis without occlusion, incidentally found to have COVID-19 with only mild respiratory symptoms. This is in contrast to the venous thrombosis and microangiopathy that has been reported in patients with severe COVID-19. Our cases suggest that even in the absence of severe disease, patients with COVID-19 may be at increased risk of thrombus formation leading to stroke, perhaps due to viral involvement of the endothelium. Further systematic study is needed, since this may have implications for primary and secondary stroke prevention in patients with COVID-19.","J Thromb Haemost","Fara, Michael G","Stein, Laura K","Skliut, Maryna","Morgello, Susan","Fifi, Johanna T","Dhamoon, Mandip S","32464707"],"abstract":["Coronavirus disease 2019 (COVID-19) is a pandemic disease currently affecting millions of people worldwide. Its neurological implications are poorly understood, and further study is urgently required. A hypercoagulable state has been reported in patients with severe COVID-19, but nothing is known about coagulopathy in patients with milder disease. We describe cases of patients in New York City presenting with stroke secondary to large vessel thrombosis without occlusion, incidentally found to have COVID-19 with only mild respiratory symptoms. This is in contrast to the venous thrombosis and microangiopathy that has been reported in patients with severe COVID-19. Our cases suggest that even in the absence of severe disease, patients with COVID-19 may be at increased risk of thrombus formation leading to stroke, perhaps due to viral involvement of the endothelium. Further systematic study is needed, since this may have implications for primary and secondary stroke prevention in patients with COVID-19."],"journal":"J Thromb Haemost","authors":["Fara, Michael G","Stein, Laura K","Skliut, Maryna","Morgello, Susan","Fifi, Johanna T","Dhamoon, Mandip S"],"date":"2020-05-29T11:00:00Z","year":2020,"_id":"32464707","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1111/jth.14938","keywords":["carotid artery thrombosis","coronavirus","infection","stroke","thrombosis"],"locations":["New York"],"countries":["United States"],"countries_codes":["USA|United States"],"topics":["Case Report"],"weight":1,"_version_":1668079521324072960,"score":118.58666}]}